Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.0K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

466
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
466
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

399
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
399
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expert proposal to characterize cardiac diseases with normal or preserved left ventricular ejection fraction and symptoms of heart failure by comprehensive echocardiography.

Clinical research in cardiology : official journal of the German Cardiac Society·2022
Same author

Diagnostic role of echocardiography for patients with heart failure symptoms and preserved left ventricular ejection fraction.

Herz·2022
Same author

Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application.

Cardiovascular drugs and therapy·2018
Same author

Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT).

Herz·2018
Same author

[Medicinal treatment of tricuspid valve regurgitation].

Herz·2017
Same author

[Current developments in telemedicine : Expectations, disappointments and hopes].

Herz·2017

Related Experiment Video

Updated: Feb 23, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

[Acute and chronic heart failure].

K-P Kresoja1,2, G Schmidt1, B Kherad1

  • 1Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow-Klinikum (CVK), Charité - Universitätsmedizin Berlin, Augustenburgerplatz 1, 13353, Berlin, Deutschland.

Herz
|September 6, 2017
PubMed
Summary

New heart failure guidelines include sacubitril/valsartan (LCZ 696) and address comorbidities. Updated recommendations also cover iron therapy, cardiac devices, and mechanical support for acute heart failure.

Keywords:
Angiotensin-receptor-neprilysin inhibitorsHeart failure treatmentIron deficiencyMechanical assist devicePrimary prophylactic ICD indication

More Related Videos

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
A Modified Technique for Transverse Aortic Constriction in Mice
04:52

A Modified Technique for Transverse Aortic Constriction in Mice

Published on: August 18, 2022

5.9K

Related Experiment Videos

Last Updated: Feb 23, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K
Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
A Modified Technique for Transverse Aortic Constriction in Mice
04:52

A Modified Technique for Transverse Aortic Constriction in Mice

Published on: August 18, 2022

5.9K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Current chronic heart failure (CHF) initial therapy includes diuretics, ACE inhibitors, beta-blockers, and MRAs.
  • The 2016 European Society of Cardiology (ESC) guidelines introduced novel therapeutic agents for CHF.

Purpose of the Study:

  • To review recent advancements in the medical and device therapy of chronic and acute heart failure.
  • To highlight the role of new agents like sacubitril/valsartan (LCZ 696) and address comorbidities.

Main Methods:

  • Review of new European Society of Cardiology (ESC) guidelines.
  • Analysis of subgroup data for sacubitril/valsartan (LCZ 696).
  • Inclusion of data on intravenous iron, cardiac devices, and mechanical circulatory support.

Main Results:

  • Sacubitril/valsartan (LCZ 696) demonstrates benefits across various comorbidities including renal insufficiency, diabetes, and hypotension.
  • New data support intravenous iron substitution and provide updated indications for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT).
  • Medical therapy for acute heart failure remains limited, with mechanical circulatory support, such as extracorporeal membrane oxygenation (ECMO), recommended for non-responders.

Conclusions:

  • Angiotensin-receptor-neprilysin inhibitors represent a significant advancement in chronic heart failure management.
  • Comprehensive updates address device therapy and novel treatments for heart failure patients with complex conditions.
  • Mechanical circulatory support is crucial for managing acute heart failure when medical therapy fails.